文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

参附注射液对脓毒症或脓毒性休克患者细胞免疫及临床结局的改善作用

Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock.
PubMed 文献 · Am J Emerg Med · 2016-09-07
一句话结论参附注射液100mL每24小时一次连用7天可改善脓毒性休克患者细胞免疫及部分临床结局,但28天死亡率无显著差异。

该研究将脓毒症患者随机分为参附注射液组(100mL每24小时一次,连用7天)与安慰剂组,均在常规治疗基础上给药。157例完成研究(参附组78例,安慰剂组79例)。参附组外周血CD4+和CD8+ T细胞升高、单核细胞HLA-DR表达上调,内毒素刺激后单核细胞肿瘤坏死因子α和白细胞介素6释放恢复(P<.05)。参附组血管活性药使用时间、APACHE II评分、Marshall评分及ICU住院时间(10.5±3.2天 vs 12.2±2.8天,P=.012)均优于安慰剂组,但28天死亡率无显著差异(20.5%[16/78] vs 27.8%[22/79],P=.28)。

要点

  • 参附注射液100mL每24小时一次连用7天,在常规治疗基础上用于脓毒症患者,可升高外周血CD4+和CD8+ T细胞并上调单核细胞HLA-DR表达(P<.05)。
  • 参附组血管活性药使用时间(P=.008)、APACHE II评分(P=.034)、Marshall评分(P=.01)均优于安慰剂组。
  • 参附组ICU住院时间10.5±3.2天 vs 安慰剂组12.2±2.8天(P=.012),参附组更短。
  • 28天死亡率参附组20.5%(16/78)vs 安慰剂组27.8%(22/79),无显著差异(P=.28)。
  • 参附组可恢复内毒素刺激后单核细胞肿瘤坏死因子α和白细胞介素6的释放(P<.05)。

适用人群与场景

  • 脓毒症患者,随机接受参附注射液或安慰剂加常规治疗;160例中3例因方案违背和撤回知情同意被排除分析,157例完成研究(参附组78例,安慰剂组79例)。

处置流程与药物剂量

  • 参附注射液100mL每24小时一次,连用7天,在常规治疗基础上给药(原文未写明给药途径)。
  • 免疫学参数在治疗后第1、3、7天采集,临床结局随访至28天。

研究设计与关键结果

  • 随机对照研究,157例完成分析(参附组78例,安慰剂组79例);参附组较安慰剂组升高外周血CD4+和CD8+ T细胞、上调单核细胞HLA-DR表达(P<.05)。
  • 参附组恢复内毒素刺激后单核细胞肿瘤坏死因子α和白细胞介素6释放(P<.05)。
  • 参附组血管活性药使用时间(P=.008)、APACHE II评分(P=.034)、Marshall评分(P=.01)优于安慰剂组。
  • 参附组ICU住院时间10.5±3.2天 vs 安慰剂组12.2±2.8天(P=.012),参附组更短。
  • 28天死亡率参附组20.5%(16/78)vs 安慰剂组27.8%(22/79),无显著差异(P=.28)。

证据类型、等级与局限

  • 研究论文(随机对照研究);原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为参附注射液可增强脓毒性休克患者的细胞免疫,可能是脓毒性休克患者有前景的辅助治疗。
  • 原文显示参附组28天死亡率与安慰剂组无显著差异(20.5%[16/78] vs 27.8%[22/79],P=.28)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To assess the efficacy of Shenfu injection (SFI) for enhancing cellular immunity and improving the clinical outcomes of patients with septic shock.

METHODS: Patients with sepsis were randomly assigned to receive either SFI at a dose of 100mL every 24hours for 7 consecutive days or a placebo in addition to conventional therapy. The immunologic parameters were collected on days 1, 3, and 7 after the above treatments, and the clinical outcomes were updated for 28days.

RESULTS: Of these160 patients, 3 were excluded from the analysis due to protocol violation and withdrawal of consent; thus, 157 completed the study (78 in the SFI group and 79 in the placebo group). We found that SFI increased both CD4+ and CD8+ T cells in peripheral blood and up-regulated HLA-DR expression in monocytes (P<.05). Furthermore, SFI was also found to restore ex vivo monocytic tumor necrosis factor α and interleukin 6 proinflammatory cytokine release in response to the endotoxin (P<.05). Importantly, the SFI group showed better clinical outcomes than did the placebo group in terms of the duration of vasopressor use (P=.008), Acute Physiology and Chronic Health Evaluation II score (P=.034), Marshall score (P=.01), and length of intensive care unit stay (10.5±3.2 vs 12.2±2.8days; P=.012). However, the 28-day mortality rate was not significantly different between the SFI (20.5%; 16/78) and placebo groups (27.8%; -22/79; P=.28).

CONCLUSION: These findings suggest that SFI can enhance the cellular immunity of patients with septic shock and could be a promising adjunctive treatment for patients with septic shock.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Zhang N, Liu J, Qiu Z, et al. Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock. Am J Emerg Med. 2016. PMID: 28029485. doi:10.1016/j.ajem.2016.09.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。